Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, randomized, double-blind, double-dummy study in postmenopausal women with low bone mineral density to compare the effects of a single dose of i.v. [intravenous] zoledronic acid 5 mg, with daily oral raloxifene 60 mg OD [once daily] on bone turnover markers.

Trial Profile

A multi-center, randomized, double-blind, double-dummy study in postmenopausal women with low bone mineral density to compare the effects of a single dose of i.v. [intravenous] zoledronic acid 5 mg, with daily oral raloxifene 60 mg OD [once daily] on bone turnover markers.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary) ; Raloxifene
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 11 Sep 2009 Results presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research.
    • 16 Dec 2008 Actual trial completion date identified as July 2008 from ClinicalTrials.gov.
    • 16 Dec 2008 Actual patient number identified as 110 from ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top